Woodline Partners’s Charles River Laboratories CRL Stock Holding History

Woodline Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.33M	Sell	7,713 -342,954	-98%	-$63.6M	0.01%	847
2025 Q4	$70M	Buy	+350,667	New	+$63.6M	0.27%	84
2025 Q3	–	Sell	-208,552	Closed	-$31.6M	–	917
2025 Q2	$31.6M	Buy	+208,552	New	+$27.8M	0.17%	176
2024 Q2	–	Sell	-16,780	Closed	-$4.55M	–	580
2024 Q1	$4.55M	Buy	+16,780	New	+$4.01M	0.04%	370
2021 Q4	–	Sell	-12,426	Closed	-$5.13M	–	716
2021 Q3	$5.13M	Sell	12,426 -23,450	-65%	-$9.74M	0.08%	246
2021 Q2	$13.3M	Buy	35,876 +4,140	+13%	+$1.38M	0.25%	108
2021 Q1	$9.2M	Buy	31,736 +5,533	+21%	+$1.54M	0.2%	125
2020 Q4	$6.55M	Buy	+26,203	New	+$6.24M	0.17%	145

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Woodline Partners's CRL Position: Q1 2026 in Review

Woodline Partners reduced its Charles River Laboratories (CRL) stake by 98% in Q1 2026, selling an estimated $63.6M and leaving 7,713 shares worth $1.33M. The position accounts for 0.01% of the portfolio, ranked #847.

Woodline Partners first reported a position in CRL in Q4 2020 and has held it in 8 quarters since. The position peaked at $70M in Q4 2025. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Woodline Partners held 7,713 shares of Charles River Laboratories worth $1.33M as of Q1 2026.
Woodline Partners sold 342,954 Charles River Laboratories shares in Q1 2026, an estimated $63.6M.
Charles River Laboratories made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #847 holding.
Woodline Partners first reported a position in Charles River Laboratories in Q4 2020 and has held it in 8 quarters since.
Woodline Partners's Charles River Laboratories position peaked at $70M in Q4 2025.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.